|
Site |
Stage/Description |
Protocol Title |
| Cervix | Treated with radical hysterectomy / lymph node dissection |
None |
|
|
No prior treatment, limited to the pelvis: Stage IB2, IIA, IIB, IIIB, IVA |
None |
| One prior treatment (performance status 0 -2) |
GOG 127V: ABI-007 (Suspended) |
| Pelvic / para-aortic lymphademectomy |
GOG 221: Glycoprotein & Glycan profiling |
| Persistent or Recurrent |
GOG 0227E: Cetuximab |
| Vulvar Malignancies | Locally advanced and squamous cell | GOG 205: Radiation therpay and weekly Cisplatin
GOG 0173: Intraoperative lymphatic mapping & Sentinel node identification |
| Ovary |
Bone Mineral Denisty |
GOG 215: Zoledronic acid versus observation for women who have risk reducing surgery that removed both ovaries |
| Recurrent and Platinum sensitive |
GOG 213: Carboplatin and Paclitaxel versus Carboplatin, Paclitaxel and Bevacizumab, followed by Bevacizumab and cytoreductive surgery |
| Recurrent and Platinum resistant |
GOG 0126R: Abraxane |
| Stromal tumors |
GOG 187: Paclitaxel as second line therapy |
| Cancer of the Fallopian Tube |
Biochemical (Rising CA-125) recurrence only |
NONE |
| Recurrent and Platinum sensitive |
GOG 213: Carboplatin and Paclitaxel versus Carboplatin, Paclitaxel and Bevacizumab, followed by Bevacizumab and cytoreductive surgery |
| Recurrent and Platinum resistant |
GOG 0126R: Abraxane |
| Epithelial Ovarian/ Primary Peritoneal cancer |
Biochemical (Rising CA-125) Recurrence Only |
NONE |
| Suboptimal, residual disease--Stage III / IV | GOG 0218: Carboplatin and Paclitaxel with Bevacizumab versus Carboplatin and Paclitaxel with Placebo |
| Complete response to primary Platinum / Taxane Chemotherapy | GOG 0212: Paclitaxel once every 4 weeks for 12 treatments versus Xyotax once every 4 weeks X 12 treatment versus no further treatment |
| Recurrent and Platinum sensitive | GOG 213: Carboplatin and Paclitaxel versus Carboplatin, Paclitaxel and Bevacizumab, followed by Bevacizumab and cytoreductive surgery
|
| Recurrent and Platinum resistant |
GOG 0126R: Abraxane |
| Persistent/Recurrent | GOG 170M: Dasatinib
|
| Endometrial | Stage IB (Grade 3), Stage IC (Grade 1-3), Stage IIA or IIB |
None |
| |
Stage III/IV |
GOG 0209: Doxorubicin / Cisplatinum / Paclitaxel / G-CSF versus Carboplatin / Paclitaxel
GOG 232C: Paclitaxel, Carboplatin and BSI-201 |
| Recurrent / Persistent Disease
|
No prior treatment
|
GOG 0209: Doxorubicin / Cisplatinum / Paclitaxel / G-CSF versus Carboplatin / Paclitaxel
GOG 232C: Paclitaxel, Carboplatin and BSI-201 |
| |
Any number of prior treatments |
GOG 188 Faslodex
|
| Carcinosarcoma |
No prior treatment |
NONE |
| Prior treatments |
NONE |
| Leiomyosarcoma |
No prior treatments |
NONE |
| Prior treatments |
GOG 87M: Trabectedin Suspended |
Breast Cancer Clinic
